Abstract

Massive hemoptysis is a stressful and life-threatening event that can occur in lung cancer patients. The management of this event is usually challenging, and can involve surgery, embolization, and bronchoscopy. Unfortunately, while surgery can offer a definitive solution to hemoptysis, lung cancer patients are often excluded from this approach. On the other hand, bronchial arterial embolization rarely results in long-term control of bleeding.

Endoscopy allows a skilled physician to perform mechanical tamponade or laser photocoagulation of bleeding lesions and preserve the main airways. While endoscopic stent placement is usually performed in order to treat stenosis, it has been occasionally employed to isolate and mechanically block the bleeding sites within the bronchial tree.

We present the cases of two patients suffering from lung cancer-related life-threatening hemoptysis; both patients were successfully treated by positioning a silicone stent during emergency bronchoscopy. Subsequently, we present a concise review of the available literature.

Introduction

Hemoptysis is an alarming and sometimes dangerous event occurring in 19-32% of lung cancer patients. The reported mortality rate for mild and moderate hemoptysis is 2.5% and 6%, respectively, while massive events, albeit uncommon (5-15%) are lethal in 38% of cases; notably, the mortality rate of hemoptysis related to lung cancer is higher compared to other causes [1].

The treatment options for this event include pharmacologic measures such as antifibrinolytic agents, vascular embolization, endoscopic procedures, and surgical resection. In particular, endoscopy has a relevant role in the emergency management of massive hemoptysis, as an urgent rigid bronchoscopy or a flexible bronchoscopy inside a tracheal tube is efficient in clearing the airways, tamponing the bleeding and therefore preserving ventilation, provided that the procedure is performed by skilled personnel; however, the long-term efficacy of the known endoscopic procedures is reportedly limited [2,3].

Here we describe two cases of patients with massive hemoptysis who underwent endoscopic treatment with the aim of stopping bleeding permanently.

Case Report

Case 1

The first case report involves a 51-year-old woman affected by adenocarcinoma of the lung; no relevant bleeding diathesis or anticoagulant/antiaggregant treatment was reported. The patient had a large neoplastic lesion involving the upper right lobe, as well as multiple small lesions in both lungs, mediastinal lymphadenopathies, and right pleural effusion (stage IV). The patient was a former smoker (30 packs/years). The research for actionable mutations of the epidermal growth factor receptor (EGFR) gene or translocations of the anaplastic lymphoma kinase (ALK) gene was negative, thus the patient received a chemotherapy combination of cisplatin plus pemetrexed for 4 cycles; the treatment was substantially well tolerated, and no significant reduction in platelet count was reported. Notably, the patient reported episodes of mild hemoptysis since the time of the diagnosis.

Six months after the diagnosis, the patient was referred to the emergency department of the San Martino Hospital - National Institute for Cancer Research for an episode of moderate hemoptysis, where a computed tomography (CT)-scan showed increase of the tumor mass in the right upper lobe with involvement of the right upper lobe bronchus with occlusion of its ostium; the invading neoplastic tissue was treated with endoscopic laser photocoagulation (diode laser), resulting in marked reduction of the bleeding.
Case Report

Case 2

The second case involves a 78-year-old male former smoker (40 pack/years) affected by a squamous cell carcinoma in the lower lobe of the right lung; no relevant bleeding diathesis or anticoagulant/antiaggregant treatment was reported. Due to the size of the tumor, the patient was excluded from curative surgery and therefore considered eligible for chemotherapy followed by thoracic radiation therapy. The patient received 2 cycles of carboplatin plus etoposide from August 2015 to September 2015, followed by a CT-scan showing progressive disease in the right lung; for this reason, the planned radiation therapy was omitted and the patient received second-line treatment with Nivolumab.

Since February 2016, the patient had been suffering from episodic blood-tinged sputum; in June 2016, a progressive worsening of the bleeding was observed, until he had to be taken to the emergency room for an episode of massive hemoptysis. During bronchoscopy, an evident intra-bronchial disease progression was observed, with bleeding neoplastic tissue reaching the entrance of the intermediate bronchus. A diode laser photocoagulation therapy was performed using a flexible bronchoscope, but it did not prove sufficiently effec-

Figure 1. Relevant images of the Case Report 1. A) Coronal and B) sagittal CT scans after insertion of the silicone stent. C) Dumon stent placed in the right main bronchus.
tive in stopping the bleeding. On the basis of the experience that had been developed in the previous case, the decision of inserting a stent in order to stop the hemorrhage was taken. However, at that time a suitable closed distal stent was not readily available in the pulmonology unit; hence, a 13x25 mm silicone stent was closed in its distal part with a suture thread and subsequently positioned in the intermediate bronchus to apply a mechanical tamponade (Figure 2). The procedure was immediately effective and no more hemoptysis episodes were reported; after the hospitalization, the patient resumed its planned anti-neoplastic treatment and he is currently receiving Nivolumab.

Discussion

Hemoptysis is a common symptom in lung cancer and is the terminal event in 3% of the cases. Hemoptysis often increases with the progression of the disease and in particular in the endoscopic progression. The presence of hemoptysis greatly impacts the quality of life of lung cancer patients; even episodes of mild or moderate hemoptysis are often perceived as stressful events and imply the possibility of a massive bleeding, which is always a dangerous and frightening occurrence for the patients and requires prompt medical intervention. To date there is no clear consensus on the definition of massive hemoptysis. Currently, rather than using a quantitative definition, it is preferred to define massive hemoptysis based on its clinical consequences, such as respiratory failure and hemodynamic instability [4].

Massive hemoptysis in patients with advanced thoracic malignancies can be difficult to manage, due to the global conditions of the patients and cancer-related comorbidities; in such cases, bleeding can be caused by necrosis of a tumor, rupture of small blood vessels in the area, or tumor invading one of the pulmonary blood vessels [5]. In such cases, the first step is to define the site of hemorrhage, as this information is critical for the subsequent steps; a CT scan can locate the site of bleeding in 70-88% of cases [6]. As one might expect, respiratory and hemodynamic conditions affect the patient’s course and need to be promptly managed. If marked bleeding causes acute respiratory failure, an endoscopic procedure with rigid bronchoscope performed by skilled personnel is required, as it allows the physician to remove blood and clots, use blocking devices as the balloon, and to perform mechanical tamponade, thus preserving ventilation. In the current clinical practice, however, not all bronchoscopists are able to use a rigid bronchoscope;
by consequence, during a massive hemoptysis it is necessary to intubate the patient with an endotracheal tube using a flexible bronchoscope. In most cases, endobronchial tamponade offers only temporary relief and does not result in long-term benefit [7]. Bronchial artery embolization (BAE) is a therapeutic modality for life-threatening massive hemoptysis. This modality has revolutionized management of these events, being a less invasive but reliable procedure that leads to excellent short-term therapeutic outcomes (immediate decrease or resolution of bleeding in most cases) [8]. If needed, BAE can be repeated multiple times; however, bleeding relapse is very frequent in cancer patients, whose prognosis remains poor [9]. Another possible option for severe hemoptysis is surgery; this procedure is often resolutively, as it is meant to remove the bleeding cause, but its applicability in the case of lung cancer patients is extremely limited due to technical difficulties and the general conditions of oncologic patients.

In 2010, Sakr and Dutau published an update on the role on the bronchoscopic management of massive hemoptysis [3]. In this publication, they proposed a management algorithm in which the choice between BAE and surgery is the last step after more conservative approaches [3]. However, in a significant number of cases, BAE was ineffective and surgery was not feasible; therefore, other therapeutic options are highly advised in this setting. During bronchoscopy, bronchial stents are normally intended to recanalize the airway in case of neoplastic obstruction and only few published cases involve their use with the aim of tamponing a neoplastic hemorrhage. In the two reported cases, tamponade with a silicone stent in two different sites, led to the definitive cessation of bleeding; in the second case, the modified silicone stent was effective and even allowed the patient to resume his systemic anti-neoplastic treatments.

In order to identify the available literature, we performed a PubMed research using the following parameters: (‘endobronchial stent’ OR ‘airway stent’) AND (‘hemoptysis’ OR ‘bleeding’ OR ‘hemorrhage’); 20 publications were found, only 3 of them actually related to the subject. An additional research using ‘hemoptysis’ and ‘silicone stent’ showed a single publication [10]. The global number of published cases is reported in Table 1. The total number of reported patients, including our cases, is 8. The median age at the time of the procedure was 62 years (range: 46-78), and the male/female ratio is 6:2; all the reported cases were affected by non-small cell lung cancer, but the exact histology was defined only in 4 cases (1 adenocarcinoma and 3 squamous cell carcinomas). Only 3 out of 8 patients had received other treatments for hemoptysis before undergoing stent placement. The median time from diagnosis of lung cancer to treatment with stents was 12 months (range: 5-17 months), excluding a case where the bleeding was iatrogenic (following a bronchial biopsy). In 5 cases, a covered nitinol stent was employed, while in another case a Y-silicone stent was placed on a secondary carina and straight silicone stents were placed in the two cases managed within our institution. In six cases, the stent placement resulted in bleeding cessation; in one case, the bleeding was only briefly reduced and, ultimately, the treatment was not considered effective. The median survival after stent insertion was 90 days (range: 2-120 days). In six patients, hemoptysis was not the cause of death, and one patient is currently alive [5, 10-12].

Table 1. Patient and treatment characteristics.

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Gender</th>
<th>Age</th>
<th>Histology</th>
<th>Previous hemoptysis treatment</th>
<th>Time from diagnosis (months)</th>
<th>Tumor site</th>
<th>Stent (mm)</th>
<th>Stent site</th>
<th>Stop bleeding</th>
<th>Survival (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandes 2008 [11]</td>
<td>F 72</td>
<td>NSCLC</td>
<td>—</td>
<td>17</td>
<td>LLL</td>
<td>Poliflex 8x20 CN stent 14x60</td>
<td>LLL LMB-LUL</td>
<td>Yes</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Dalar 2014 [10]</td>
<td>M 52</td>
<td>NSCLC</td>
<td>—</td>
<td>Iatrogenic</td>
<td>LUL</td>
<td>Y silicon stent 14x10x10</td>
<td>LMB-LLL-LUL</td>
<td>Yes</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>This study 2016</td>
<td>F 51</td>
<td>ADC</td>
<td>RT - Laser-BAE</td>
<td>6</td>
<td>RUL</td>
<td>S stent 13x30</td>
<td>IB-RMB</td>
<td>Yes</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>This study 2016</td>
<td>M 78</td>
<td>SCC</td>
<td>Laser</td>
<td>12</td>
<td>RLL</td>
<td>S stent 13x25</td>
<td>IB</td>
<td>Yes</td>
<td>AWD (70)</td>
<td></td>
</tr>
</tbody>
</table>

F: female; M: male; NSCLC: non-small cell lung cancer; SCC: squamous cell carcinoma; ADC: adenocarcinoma; RT: radiotherapy; LLL: left lower lobe; LMB: left main bronchus; RUL: right upper lobe; LUL: left upper lobe; CN stent: covered nitinol stent; S stent: silicon stent; RLL: right lower lobe; RMB: right main bronchus; IB: intermediate bronchus; AWD: alive with disease.
References